GRAIL (NASDAQ:GRAL – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare GRAIL to similar businesses based on the strength of its risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
47.8% of shares of all “Biotechnology” companies are held by institutional investors. 1.8% of GRAIL shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares GRAIL and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| GRAIL | $166.60 million | -$408.35 million | -10.75 |
| GRAIL Competitors | $746.55 million | $11.18 million | -18.46 |
GRAIL’s peers have higher revenue and earnings than GRAIL. GRAIL is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a breakdown of recent ratings and target prices for GRAIL and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GRAIL | 1 | 6 | 5 | 0 | 2.33 |
| GRAIL Competitors | 9920 | 15331 | 45733 | 1601 | 2.54 |
GRAIL presently has a consensus target price of $128.80, suggesting a potential upside of 26.15%. As a group, “Biotechnology” companies have a potential upside of 109.13%. Given GRAIL’s peers stronger consensus rating and higher probable upside, analysts clearly believe GRAIL has less favorable growth aspects than its peers.
Volatility & Risk
GRAIL has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500. Comparatively, GRAIL’s peers have a beta of -1.85, meaning that their average stock price is 285% less volatile than the S&P 500.
Profitability
This table compares GRAIL and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GRAIL | -243.80% | -16.13% | -14.38% |
| GRAIL Competitors | -12,516.26% | -215.91% | -31.70% |
Summary
GRAIL peers beat GRAIL on 8 of the 13 factors compared.
GRAIL Company Profile
GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.
Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.
